P. Schmid

520P Long-term safety and efficacy of first-line atirmociclib + letrozole for the treatment of patients with HR+/HER2− metastatic breast cancer (mBC)

Timothy A. Yap, M.E. Magallanes Maciel, Baojun Xu, D.L. Kaen et autres

us, mx, cn, ar, gb, my (code pays fourni par la source)

Abstract P5-03-11: DEMETHER: A single-arm phase II trial to evaluate the efficacy & safety of subcutaneous pertuzumab & trastuzumab maintenance after induction treatment w/ trastuzumab deruxtecan (T-DXd) for previously untreated HER2-positive advanced breast cancer

Javier Cortés, Juan Garcia, Gabriele Antonarelli, Alessandra Gennari et autres

Abstract Background: HER2 (human epidermal growth factor receptor 2) is overexpressed in 15-20% of all breast cancers. Pertuzumab combined with trastuzumab and taxanes is the standard first-line therapy for HER2-positive advanced breast cancer (ABC) based on the results from CLEOPATRA trial. T-DXd …

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

Valentina Gambardella, MK Accordino, Philippe L. Bédard, A. Cervantes et autres

BACKGROUND: Inavolisib is a potent and selective PI3Kα inhibitor that promotes degradation of mutated p110α. We report safety from a phase I/Ib dose-escalation/-expansion study (GO39374; NCT03006172) of inavolisib alone or in combination therapies in PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced breast cancer. …

es, us, ca, fr, gb (code pays fourni par la source)

90P Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+/HER2− metastatic breast cancer (mBC)

P. Schmid, M.R. Sharma, Antonio Giordano, Scott J. Howell et autres

Atirmociclib (PF-07220060) is a highly selective and potent CDK4 inhibitor with sparing of CDK6. In an ongoing phase 1/2a trial (NCT04557449), atirmociclib + ET demonstrated favorable safety, tolerability, clinical activity, and robust pharmacodynamic (PD) activities in patients (pts) with HR+/HER2− mBC (Yap. …

gb, us, mx, ar (code pays fourni par la source)

Redefining clinical trial strategic design to support drug approval in medical oncology

Gabriele Antonarelli, José Manuel Pérez-García, María Gión, Hope Rugo et autres

it, es, us, gb, de (code pays fourni par la source)

7O Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) in previously untreated HER2+ metastatic breast cancer (mBC): Clinical efficacy and exploratory subgroup analyses in DESTINY-Breast07

Fabrice André, Giulia Fabbri, R. McEwen, Tereza Vaclová et autres

fr, sg, us, gb, nl, pl, au (code pays fourni par la source)

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

P. Schmid, M.F. Mosele, Giancarlo Pruneri, H.J. Burstein et autres

us (code pays fourni par la source)

24TiP A phase III, randomized study of adjuvant sacituzumab tirumotecan (sac-TMT) plus pembrolizumab vs treatment of physician’s choice (TPC) in patients with TNBC who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery

Rebecca Dent, Rina Hui, Y.H. Park, P. Schmid et autres

sg, hk, kr, gb, us, es (code pays fourni par la source)

First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.

Antonio Giordano, Manish Sharma, Anja Williams, P. Schmid et autres

3108 Background: PF-07220060 is a novel, highly selective CDK4 inhibitor with significant CDK6 sparing. Preliminary data have been reported for the monotherapy dose-escalation cohort (Part 1A) and ET combination dose-finding cohorts (Parts 1B-C) in the first-in-human study of PF-07220060 in patients (pts) …

us, gb, mx, cn (code pays fourni par la source)

185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)

C. Anders, S. Loi, Erika Hamilton, Komal Jhaveri et autres

DEBBRAH, ROSET-BM, TUXEDO-1, and a pooled DB-01, -02, -03 analysis indicate robust efficacy of T-DXd in pts with stable/active BM; however, efficacy in pts with BM is not yet fully established. DB-07 is a phase Ib/II, multicenter, open-label study exploring the safety, …

us, au, gb, tr, kr, br, pl, fr (code pays fourni par la source)

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

P. Tarantino, Giulia Viale, Michael F. Press, Xin Hu et autres

us, it, cn, fr, gr, ch, es, de, gb, au (code pays fourni par la source)

214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study

P. Schmid, J. Cortés, F. Marmé, H. S. Rugo et autres

gb, de, us, es, fr (code pays fourni par la source)